We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-14.23%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$4.99B
AUM Growth
-$1.5B
Cap. Flow
-$539M
Cap. Flow %
-10.81%
Top 10 Hldgs %
44.72%
Holding
159
New
13
Increased
22
Reduced
36
Closed
24

Top Buys

Rank Stock Value
1
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$47.6M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$33.3M
3
NVRO
NEVRO CORP.
NVRO
+$32.7M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$32.1M
5
PEN icon
Penumbra
PEN
+$31.9M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$104M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$92.4M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$46.5M
4
KOD icon
Kodiak Sciences
KOD
+$44.1M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$37.1M

Sector Composition

Rank Sector Weight
1 Healthcare 81.81%
2 Financials 0.77%
3 Industrials 0.12%
4 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$261M 5.23%
27,555,845
+996,402
+4% +$9.34M
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
$256M 5.12%
4,527,993
-321,919
-7% -$18.4M
LIAN
3
DELISTED
LianBio American Depositary Shares
LIAN
$209M 4.19%
56,319,960
– –
IOVA icon
4
Iovance Biotherapeutics
IOVA
$2.04B
$203M 4.07%
12,201,261
+2,073,320
+20% +$32.1M
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$196M 3.92%
2,380,710
-903,073
-28% -$92.4M
AGRX
6
DELISTED
Agile Therapeutics
AGRX
$178M 3.57%
10,647
– –
CERE
7
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$178M 3.57%
5,086,727
– –
HZNP
8
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$143M 2.86%
1,357,903
-380,237
-22% -$37.1M
GBT
9
DELISTED
Global Blood Therapeutics, Inc.
GBT
$135M 2.7%
3,892,493
+442,578
+13% +$13.2M
CRNX icon
10
Crinetics Pharmaceuticals
CRNX
$8.88B
$113M 2.27%
5,163,517
– –
MGTX icon
11
MeiraGTx Holdings
MGTX
$1.08B
$96.2M 1.93%
6,948,277
– –
RXDX
12
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$92.2M 1.85%
2,440,582
-732,203
-23% -$28.9M
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$87.9M 1.76%
5,225,415
-1,254,585
-19% -$18.5M
VBIV
14
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$86.9M 1.74%
1,744,500
– –
OM icon
15
Outset Medical
OM
$86.4M
$85.5M 1.71%
125,560
+1,334
+1% +$803K
APLS
16
DELISTED
Apellis Pharmaceuticals
APLS
$75.3M 1.51%
1,481,700
+30,000
+2% +$1.32M
XENE icon
17
Xenon Pharmaceuticals
XENE
$6.1B
$73.7M 1.48%
2,411,447
– –
ALBO
18
DELISTED
Albireo Pharma Inc
ALBO
$70.4M 1.41%
2,360,139
– –
RAPT
19
DELISTED
RAPT Therapeutics
RAPT
$61.6M 1.23%
349,995
-15,951
-4% -$3.01M
CHRS icon
20
Coherus Oncology
CHRS
$217M
$60.6M 1.21%
4,695,848
-711,950
-13% -$9.05M
RLAY icon
21
Relay Therapeutics
RLAY
$4B
$58.2M 1.16%
1,943,097
– –
BLU
22
DELISTED
BELLUS Health Inc.
BLU
$56M 1.12%
8,136,630
+491,396
+6% +$3.17M
PRCT icon
23
Procept Biorobotics
PRCT
$1.02B
$52.1M 1.04%
1,488,284
+159,999
+12% +$3.85M
CCCC icon
24
C4 Therapeutics
CCCC
$389M
$50.5M 1.01%
2,082,723
-126,190
-6% -$3.06M
TVTX icon
25
Travere Therapeutics
TVTX
$5.17B
$47.6M 0.95%
1,845,555
– –
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Perceptive Advisors held 159 positions worth $4.99B, down 23% from $6.49B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Perceptive Advisors withdrew a net $539M in Q1 2022, closing 24 positions and reducing 36 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $104M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 85% a quarter earlier, followed by Financials and Industrials.

Against the trend, Perceptive Advisors opened a new position in CinCor Pharma, Inc. Common Stock worth $40.7M.

  • Perceptive Advisors's largest Q1 2022 buy was CinCor Pharma, Inc. Common Stock: 2,319,117 shares worth $40.7M.
  • Perceptive Advisors added most to NEVRO CORP. in Q1 2022, an estimated $32.7M increase.
  • Perceptive Advisors's biggest Q1 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $92.4M.
  • Perceptive Advisors fully exited BioMarin Pharmaceuticals in Q1 2022, selling an estimated $104M.
  • Perceptive Advisors's ten largest holdings make up 45% of its $4.99B portfolio in Q1 2022.
  • Perceptive Advisors opened 13 new positions and closed 24 in Q1 2022.
  • Perceptive Advisors's portfolio value fell 23% quarter-over-quarter to $4.99B.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.